Nymox Pharmaceutical Corp
NYMX
NYMX was delisted on the 6th of July, 2023.
2 hedge funds and large institutions have $16K invested in Nymox Pharmaceutical Corp in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
355% more capital invested
Capital invested by funds: $3.51K → $16K (+$12.5K)
100% more funds holding
Funds holding: 1 → 2 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DDC
DF Dent & Co
Baltimore,
Maryland
|
+$10.9K |
Top Sellers
NYMX Hedge Fund Activity: Q1 2025 in Review
2 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q1 2025, worth a combined $16K — up 355% from $3.51K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new NYMX positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was DF Dent & Co, opening a new position worth an estimated $10.9K.
- 2 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q1 2025, up from 1 in Q4 2024.
- Funds reported $16K of Nymox Pharmaceutical Corp stock for Q1 2025, up 355% quarter-over-quarter.
- 1 fund opened new Nymox Pharmaceutical Corp positions in Q1 2025 and 0 closed out, a net change of +1 holder.
- The largest Nymox Pharmaceutical Corp buyer in Q1 2025 was DF Dent & Co, an estimated $10.9K added.
Based on aggregated 13F filings for Q1 2025.